NCT06862206 This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
| NCT ID | NCT06862206 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Chronic Obstructive Pulmonary Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-07-11 |
| Primary Completion | 2028-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-07-11 with a primary completion date of 2028-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
Eligibility Criteria
Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.
Contact & Investigator
chen wang, PhD
PRINCIPAL INVESTIGATOR
China-Japan Friendship Hospital
Frequently Asked Questions
Who can join the NCT06862206 clinical trial?
This trial is open to participants of all sexes, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06862206 currently recruiting?
Yes, NCT06862206 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06862206 trial being conducted?
This trial is being conducted at Anhui, China, Anning, China, Beijing, China, Binzhou, China and 11 additional locations.
Who is sponsoring the NCT06862206 clinical trial?
NCT06862206 is sponsored by AstraZeneca. The principal investigator is chen wang, PhD at China-Japan Friendship Hospital. The trial plans to enroll 1,000 participants.